dc.contributor.author |
Jackson, V |
en |
dc.contributor.author |
Silva, S |
en |
dc.contributor.author |
Abbattista, M |
en |
dc.contributor.author |
Guise, Christopher |
en |
dc.contributor.author |
Bull, M |
en |
dc.contributor.author |
Ashoorzadeh, A |
en |
dc.contributor.author |
Hart, C |
en |
dc.contributor.author |
Pearce, T |
en |
dc.contributor.author |
Smaill, Jeffrey |
en |
dc.contributor.author |
Patterson, Adam |
en |
dc.coverage.spatial |
Boston, Massachusetts |
en |
dc.date.accessioned |
2015-12-14T01:13:13Z |
en |
dc.date.issued |
2015 |
en |
dc.identifier.citation |
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2015 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/27742 |
en |
dc.relation.ispartof |
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). |
en |
dc.type |
Conference Item |
en |
pubs.author-url |
http://www.aacr.org/Documents/Targets15_AbstractsPosterA.pdf |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Abstract |
en |
pubs.elements-id |
506352 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2015-11-26 |
en |